Search

Savara Inc

Открыт

СекторЗдравоохранение

5.6 0.18

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

5.51

Макс.

5.64

Ключевые показатели

By Trading Economics

Доход

-2.9M

-40M

Прибыль на акцию

-0.16

Сотрудники

70

EBITDA

-3M

-40M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+99.46% upside

Дивиденды

By Acuity

Следующий отчет о доходах

10 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-32M

1.1B

Предыдущая цена открытия

5.42

Предыдущая цена закрытия

5.6

Новостные настроения

By Acuity

48%

52%

162 / 340 Рейтинг в Healthcare

Savara Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

25 авг. 2026 г., 19:16 UTC

Event

Savara Inc announced presentations at the ERS Congress, yet shares are trading lower today, reflecting a slight decline since Monday's close.

24 авг. 2026 г., 22:01 UTC

News

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

21 авг. 2026 г., 19:36 UTC

News

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

20 авг. 2026 г., 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

19 авг. 2026 г., 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

18 авг. 2026 г., 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

17 авг. 2026 г., 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14 авг. 2026 г., 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13 авг. 2026 г., 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12 авг. 2026 г., 19:56 UTC

News

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11 авг. 2026 г., 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10 авг. 2026 г., 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7 авг. 2026 г., 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6 авг. 2026 г., 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5 авг. 2026 г., 19:36 UTC

News

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4 авг. 2026 г., 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3 авг. 2026 г., 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31 июл. 2026 г., 20:06 UTC

Event

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30 июл. 2026 г., 20:09 UTC

Event

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29 июл. 2026 г., 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28 июл. 2026 г., 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27 июл. 2026 г., 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24 июл. 2026 г., 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

21 июл. 2026 г., 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

20 июл. 2026 г., 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.

Сравнение c конкурентами

Изменение цены

Savara Inc Прогноз

Целевая цена

By TipRanks

99.46% рост

Прогноз на 12 месяцев

Средняя 11.17 USD  99.46%

Максимум 16 USD

Минимум 9 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Savara Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

162 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
help-icon Live chat